Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

Clinical trial NCT06630221 · SUSPENDED

Trial details

NCT number: NCT06630221
Sponsor: Abhay Singh, MD MPH
Status: SUSPENDED
Phase: Phase 2
Study type: INTERVENTIONAL

Myelodysplastic Syndromes Chronic Myelomonocytic Leukemia

Start date: 2025-06-17
Primary completion: 2028-01-01
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.